WASH Benefits Bangladesh Analysis of Stress Biomarkers and Growth Outcomes

Andrew Mertens

05/14/2024

## Primary findings: H1

Evidence for hypothesis 1 but not the other hypotheses.

| name | Outcome | Coefficient (95% CI) | P-value |
| --- | --- | --- | --- |
| IPF(2a)-III | LAZ Year 1 | -0.13 (-0.21, -0.06) | 0\* |
|  | WAZ Year 1 | -0.14 (-0.22, -0.06) | 0\* |
|  | WLZ Year 1 | -0.14 (-0.25, -0.04) | 0.01\* |
| 2,3-dinor-iPF(2a)-III | LAZ Year 1 | -0.19 (-0.3, -0.07) | 0\* |
| iPF(2a)-VI | LAZ Year 1 | -0.22 (-0.35, -0.1) | 0\* |
|  | WAZ Year 1 | -0.12 (-0.21, -0.03) | 0.01\* |
|  | WAZ Year 1 | -0.12 (-0.24, 0.01) | 0.06\* |
| Combined urinary oxidative stress biomarkers | LAZ Year 1 | -0.31 (-0.51, -0.11) | 0\* |
|  | WAZ Year 1 | -0.18 (-0.27, -0.08) | 0\* |
|  | WLZ Year 1 | -0.12 (-0.21, -0.02) | 0.02\* |